Consolidation/Split - IVX
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Invion Ltd. has filed a notification regarding a security consolidation or split. The consolidation will affect various securities, including ordinary shares and options. Trading in the post-consolidation securities is set to commence on a deferred settlement basis. The record date for the consolidation is specified, along with the timetable for the process. Approval from security holders is required before the consolidation can proceed.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Invion
- Invion Limited (ASX: IVX) Prostate Cancer Trial Results
- Ph 2 Prostate Cancer Results Strong Safety and 40% Response
- Invion secures funding through an institutional placement
- Agreement with Major South Korean Pharma Group Hanlim
- INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC
Later from Invion
- Invion Doses First Patient in Phase I/II Skin Cancer Trial
- Activities Report and Appendix 4C
- Oesophageal Cancer Collaboration and Funding Agreement
- Completion Of Placement to Accelerate Clinical Programs
- Share Purchase Agreement Termination and Tranche Repayment
Follow Invion into a list and get an email when it puts out news.
Follow Invion